Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Eleven brokerages cover ORKA (10 buy, 1 sell) with an average 12‑month price target of $78.90, and several firms recently raised targets (e.g., Wedbush to $85, BTIG to $78), signaling strong analyst bullishness.
• The company remains loss‑making—shares opened at about $65.55 with a market cap of $3.25B and a negative P/E; Oruka beat the most recent quarter (‑$0.45 vs. ‑$0.61 est.) but consensus forecasts expect ~‑$3.41 EPS for the current fiscal year, leaving valuation dependent on future clinical progress.
• Insiders have sold stock recently (≈23,765 shares, ~$1.09M over three months) though they still own 24.69% and institutions own 56.44%; Oruka is a clinical‑stage biotech with lead candidate ONCT‑01 in Phase 1, emphasizing binary clinical risk.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $78.90.

A number of equities analysts recently weighed in on ORKA shares. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 16th. BTIG Research increased their target price on Oruka Therapeutics from $73.00 to $78.00 and gave the company a "buy" rating in a report on Monday. UBS Group increased their target price on Oruka Therapeutics from $50.00 to $75.00 and gave the company a "buy" rating in a report on Monday, April 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Finally, Wedbush increased their target price on Oruka Therapeutics from $45.00 to $85.00 and gave the company an "outperform" rating in a report on Wednesday.

Oruka Therapeutics Stock Down 2.3%

Shares of ORKA opened at $65.55 on Thursday. The company has a market capitalization of $3.25 billion, a price-to-earnings ratio of -35.24 and a beta of -0.54. Oruka Therapeutics has a 52 week low of $8.31 and a 52 week high of $67.94. The stock's 50-day moving average price is $41.37 and its 200-day moving average price is $33.23.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. As a group, equities analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares of the company's stock, valued at $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares of the company's stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 23,765 shares of company stock valued at $1,089,745 in the last three months. Insiders own 24.69% of the company's stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new position in Oruka Therapeutics in the second quarter worth approximately $28,000. BNP Paribas Financial Markets grew its position in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada grew its position in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics in the third quarter worth approximately $39,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $85 and assigned an "outperform" rating, a notable bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
• Positive Sentiment: BTIG boosted its price target to $78, adding further analyst-driven momentum that may support buying interest. BTIG raises ORKA target to $78
• Positive Sentiment: HC Wainwright reiterated a "Buy" rating and a $70 target while publishing multi‑quarter and FY2026–FY2027 EPS forecasts FY2027: -$3.55, signaling continued analyst conviction despite losses; this sustained buy-side research supports the stock’s rally. HC Wainwright coverage
• Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan, reducing her stake ~17.3%; because the sale was pre‑planned and disclosed via SEC Form 4, it’s less likely to signal new negative information, but it can still be perceived as supply pressure. SEC Form 4
• Negative Sentiment: Consensus and firm forecasts confirm continued multi‑year losses (consensus FY current year ~ -$3.41 EPS; HC Wainwright FY2027 -$3.55), which keeps valuation reliant on future clinical/ commercial successes and may cap multiple expansion despite high price‑target activity.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.